Albumin Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Albumin Industry Market Size Be by 2025?
In the past few years, there has been a significant expansion in the size of the albumin market. The market, which is currently valued at $6.57 billion in 2024, is projected to increase to $7.18 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.3%. The factors contributing to this prominent historic growth include progress in biotechnology, a rise in the need for therapies derived from plasma, extended applications within the pharmaceutical sector, a high incidence of liver diseases, regulatory sanctioning of albumin-focused products, and the global integration of healthcare resulting in a broader market reach.

What's the Long-Term Growth Forecast for the Albumin Market Size Through 2029?
It is anticipated that the albumin market size will witness substantial growth over the coming years, with a projection to reach $10.16 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.1%. The surge in growth during the estimated period can be associated with the rising incidence of liver ailments, the growing use in regenerative medicine, an increasing elderly population, advancements in diagnostic approaches, the shift in healthcare infrastructure towards outpatient services, and heightened awareness about the need for maintaining ideal protein amounts. The projection period will likely see trends like growing therapeutic applications, increased utilization in drug delivery mechanisms, escalating demand in cell culture media, advancements in personalized medicine, progression in recombinant technology, increased awareness about hypoalbuminemia treatment, and a considerable influx of investment in research and development for pioneering albumin-related products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/albumin-global-market-report

What Are the Key Growth Drivers Fueling the Albumin Market Expansion?
The anticipated acceleration in the albumin market can be attributed to the increasing prevalence of diabetes. Defined by consistently high levels of blood sugar over a sustained period, diabetes is a metabolic disorder. The growing number of individuals suffering from this condition is linked to factors like poor diet, inactivity, hormonal imbalances, and obesity. As a vital biomarker in diabetes, albumin assists in directing insulin therapy, overseeing glycemic control, aiding diagnosis, and foreseeing complications like diabetic ket*oacidosis (DKA). Maintaining albumin within the normal range is exceedingly crucial for effective diabetes control. For example, the National Library of Medicine, a government library based in the US, revealed in January 2022 that in 2021, the worldwide prevalence of diabetes affected an estimated 10.5%, or roughly 536.6 million people aged between 20 to 79. The number is predicted to rise to 12.2% by 2045, affecting nearly 783.2 million individuals. Consequently, the climbing rate of diabetes is predicted to spur the expansion of the albumin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16333&type=smp

What Are the Key Trends Driving Albumin Market Growth?
Leading firms in the albumin market are creating novel products like animal- and human-origin-free recombinant albumin, which incorporates enhanced features to better accommodate consumer needs. This type of albumin is synthesized using non-mammalian systems, such as yeast, excluding any components sourced from humans or animals. For example, in March 2023, Albumedix, a UK producer of recombinant human albumin, partnered with Heartseed Inc., a Japan-based biotech firm in the clinical-stage, to introduce Recombin. This pivotal excipient will be deployed in the manufacture of HS-001, Heartseed's experimental cell therapy, in congruence with the start of its primary clinical trial involving human subjects. This cooperation signifies a remarkable advancement in the progression of HS-001, which is anticipated to transform the approach to treating various ailments. Recombination's incorporation in the production process enhances the cell therapy's performance and stability, bolstering its prospective efficacy in treatment.

How Is the Albumin Market Segmented?
The albumin market covered in this report is segmented -

1) By Type: Human Serum Albumin, Bovine Serum Albumin, Recombinant Albumin
2) By Application: Therapeutics, Drug Formulation And Vaccines, Component Of Media, Other Applications
3) By Sales Channel: Business-To-Consumer (B2C), Business-To-Business (B2B)
4) By End-User: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Research Institutes

Subsegments:
1) By Human Serum Albumin: Plasma-Derived Human Serum Albumin, Recombinant Human Serum Albumin, Human Serum Albumin For Therapeutic Use (In Liver Disease, Burns), Human Serum Albumin For Drug Delivery And Research Applications
2) By Bovine Serum Albumin: Bovine Serum Albumin For Laboratory Use (In Cell Culture), Bovine Serum Albumin For Diagnostic Kits, Bovine Serum Albumin As A Stabilizer In Vaccines And Biopharmaceuticals
3) By Recombinant Albumin: Recombinant Human Albumin For Therapeutic Applications, Recombinant Albumin For Biopharmaceutical Formulation, Recombinant Albumin For Cosmetic And Personal Care Applications, Recombinant Albumin For Research And Diagnostic Applications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16333&type=smp

Which Companies Are Leading the Charge in Albumin Market Innovation?
Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.

Which Regions Are Leading the Global Albumin Market in Revenue?
North America was the largest region in the albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16333

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.